Portage Biotech
Portage Biotech is a pharmaceutical and biotech company focused on researching and developing products through clinical proof of concept, with an initial emphasis on unmet medical needs. After proof of concept, the company aims to sell or license products to large pharmaceutical companies for further development and commercialization. Portage seeks discovery and co-development partnerships in cancer, infectious disease, neurology and psychiatry, and develops novel targeted therapies, stem cell therapy, and older marketed products with novel patentable characteristics that may bring new value to patients.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
6 past transactions
Tarus Therapeutics
Acquisition in 2022
Tarus Therapeutics is a biotechnology company that specializes in cancer therapy, focusing on the role of nucleotide metabolism in cancer progression. The company's primary research initiatives target the immunosuppressive adenosine pathway within the tumor microenvironment. By addressing this pathway, Tarus Therapeutics aims to develop treatments for resistant cancers by modulating immune responses in tumors. Their innovative approach seeks to improve patient outcomes and contribute to advancements in cancer therapies.
Stimunity
Seed Round in 2020
Stimunity is a preclinical-stage biotechnology company developing drugs targeting the STING pathway to stimulate the innate immune system. Their focus is on creating therapies that help patients' bodies fight infectious diseases and cancer.
Stimunity
Seed Round in 2019
Stimunity is a preclinical-stage biotechnology company developing drugs targeting the STING pathway to stimulate the innate immune system. Their focus is on creating therapies that help patients' bodies fight infectious diseases and cancer.
SalvaRx
Acquisition in 2018
SalvaRx Ltd. develops therapies within the rapidly growing immuno-oncology market, which uses treatments designed to boost the body's natural defences to fight the cancer.
iOx Therapeutics
Convertible Note in 2018
iOx Therapeutics Ltd. operates as an immuno-oncology company. Founded in February 2015 by Professor Cerundolo, iOx Therapeutics is a spin-out from the University of Oxford started to commercialize discoveries made as part of a long-running collaboration between Oxford and the Ludwig Institute for Cancer Research. iOx intends to develop and commercialize multiple synthetic lipid compounds discovered by a research team led by Professor Cerundolo.
Stimunity
Seed Round in 2018
Stimunity is a preclinical-stage biotechnology company developing drugs targeting the STING pathway to stimulate the innate immune system. Their focus is on creating therapies that help patients' bodies fight infectious diseases and cancer.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.